These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 18344437)

  • 1. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography.
    Picchio M; Beck R; Haubner R; Seidl S; Machulla HJ; Johnson TD; Wester HJ; Reischl G; Schwaiger M; Piert M
    J Nucl Med; 2008 Apr; 49(4):597-605. PubMed ID: 18344437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-gluco-RGD autoradiography.
    Troost EG; Laverman P; Kaanders JH; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2008 Oct; 49(10):1732; author reply 1732-3. PubMed ID: 18794277
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
    Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
    J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
    Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
    J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).
    Maier FC; Kneilling M; Reischl G; Cay F; Bukala D; Schmid A; Judenhofer MS; Röcken M; Machulla HJ; Pichler BJ
    Radiat Oncol; 2011 Nov; 6():165. PubMed ID: 22118419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.
    Haubner R; Wester HJ; Reuning U; Senekowitsch-Schmidtke R; Diefenbach B; Kessler H; Stöcklin G; Schwaiger M
    J Nucl Med; 1999 Jun; 40(6):1061-71. PubMed ID: 10452325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy.
    Busk M; Horsman MR; Jakobsen S; Keiding S; van der Kogel AJ; Bussink J; Overgaard J
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1202-12. PubMed ID: 18313528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
    Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ
    J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
    Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
    Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide.
    Chen X; Park R; Tohme M; Shahinian AH; Bading JR; Conti PS
    Bioconjug Chem; 2004; 15(1):41-9. PubMed ID: 14733582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolabeled RGD uptake and alphav integrin expression is enhanced in ischemic murine hindlimbs.
    Lee KH; Jung KH; Song SH; Kim DH; Lee BC; Sung HJ; Han YM; Choe YS; Chi DY; Kim BT
    J Nucl Med; 2005 Mar; 46(3):472-8. PubMed ID: 15750161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD.
    Pichler BJ; Kneilling M; Haubner R; Braumüller H; Schwaiger M; Röcken M; Weber WA
    J Nucl Med; 2005 Jan; 46(1):184-9. PubMed ID: 15632051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three
    Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
    Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
    Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
    J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis.
    Chen X; Park R; Shahinian AH; Tohme M; Khankaldyyan V; Bozorgzadeh MH; Bading JR; Moats R; Laug WE; Conti PS
    Nucl Med Biol; 2004 Feb; 31(2):179-89. PubMed ID: 15013483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
    Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
    Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice.
    Jeong JM; Hong MK; Chang YS; Lee YS; Kim YJ; Cheon GJ; Lee DS; Chung JK; Lee MC
    J Nucl Med; 2008 May; 49(5):830-6. PubMed ID: 18413379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
    Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of [125I]IPOS as a molecular imaging probe for hypoxia-inducible factor-1-active regions in a tumor: comparison among single-photon emission computed tomography/X-ray computed tomography imaging, autoradiography, and immunohistochemistry.
    Ueda M; Kudo T; Mutou Y; Umeda IO; Miyano A; Ogawa K; Ono M; Fujii H; Kizaka-Kondoh S; Hiraoka M; Saji H
    Cancer Sci; 2011 Nov; 102(11):2090-6. PubMed ID: 21824221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET.
    Iqbal R; Kramer GM; Verwer EE; Huisman MC; de Langen AJ; Bahce I; van Velden FH; Windhorst AD; Lammertsma AA; Hoekstra OS; Boellaard R
    J Nucl Med; 2016 Apr; 57(4):530-5. PubMed ID: 26659349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.